Dravet Syndrome clinical trials at UCSF

3 in progress, 2 open to eligible people

Dravet syndrome is a genetic epilepsy marked by frequent, prolonged seizures in young children. UCSF is enrolling infants and children in an early safety and efficacy study of a new medication. UCSF is also involved in a randomized, placebo-controlled study of an oral therapy.

Showing trials for

  • EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

    open to eligible people ages 2 years and up

    This is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole hydrochloride (EPX-100) as adjunctive therapy in children and adult participants with Dravet syndrome (DS).

    San Francisco, California and other locations

  • ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome

    open to eligible people ages 6 months to 17 years

    ENDEAVOR is a Phase 1/2, 2-part, multicenter study to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet syndrome aged ≥6 to <36 months (Part 1A), aged ≥48 months to <18 years (Part 1B), and aged ≥6 to <48 months (Part 2). Part 1A follows an open-label, dose-escalation design, Part 1B follows an open-label design, and Part 2 is a randomized, double-blind, sham delayed-treatment control study.

    San Francisco, California and other locations

  • STK-001 for Patients With Dravet Syndrome

    Sorry, in progress, not accepting new patients

    Stoke Therapeutics is evaluating the long-term safety & tolerability of repeated doses of zorevunersen (STK-001) in patients with Dravet syndrome who previously participated in studies of zorevunersen. Change in seizure frequency and overall clinical status, and quality of life will be measured as secondary endpoints in this open-label study.

    San Francisco, California and other locations

Our lead scientists for Dravet Syndrome research studies include .

Last updated: